Active cytomegalovirus replication in patients with coronary disease

References

• Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002; 91: 281–91
   PubMed Web of Science ®Google Scholar
• Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: Associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation. 2000; 102: 833–9
   PubMed Web of Science ®Google Scholar
• Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001; 103: 45–51
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997; 91: 119–26
   PubMed Web of Science ®Google Scholar
• Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol. 1994; 42: 170–4
   PubMed Web of Science ®Google Scholar
• Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol. 1990; 136: 23–8
   PubMed Web of Science ®Google Scholar
• Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, Ruchti F, et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell. 1999; 99: 511–20
   PubMed Web of Science ®Google Scholar
• Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996; 335: 624–30
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation. 1998; 98: 2796–9
   PubMed Web of Science ®Google Scholar
• Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, Shearer GM, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000; 85: 140–6
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G, et al. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation. 2001; 103: 2915–21
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation. 2000; 102: 1917–23
   PubMed Web of Science ®Google Scholar
• Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004; 109: II42–8
   PubMed Web of Science ®Google Scholar
• Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation. 2003; 107: 258–63
   PubMed Web of Science ®Google Scholar
• Soderberg C, Larsson S, Bergstedt-Lindqvist S, Moller E. Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol. 1993; 67: 3166–75
   PubMed Web of Science ®Google Scholar
• Haider AW, Wilson PW, Larson MG, Evans JC, Michelson EL, Wolf PA, et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: A prospective study. J Am Coll Cardiol. 2002; 40: 1408–13
   PubMed Web of Science ®Google Scholar
• Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991; 72(Pt 9)2059–64
   PubMed Web of Science ®Google Scholar
• Britt WA, Alford CA. Cytomegalovirus. Fields Virology. Lippincott-Raven Publishers, Philiadelphia 1996; 2: 2493–2523
   Google Scholar
• Mori T, Kameda H, Ogawa H, Iizuka A, Sekiguchi N, Takei H, et al. Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy. J Rheumatol. 2004; 31: 1349–51
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Fischer SH, Fahle GA, Calhoun LB, Childs RW, Barrett AJ, et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis. 2003; 188: 967–72
   PubMed Web of Science ®Google Scholar
• Mehta SK, Stowe RP, Feiveson AH, Tyring SK, Pierson DL. Reactivation and shedding of cytomegalovirus in astronauts during spaceflight. J Infect Dis. 2000; 182: 1761–4
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C, Streblow DN, Fish KN, Allan-Yorke J, Smith PP, Nelson JA. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol. 2001; 75: 7543–54
   Google Scholar
• Jonasson L, Tompa A, Wikby A. Expansion of peripheral CD8+ T cells in patients with coronary artery disease: relation to cytomegalovirus infection. J Intern Med. 2003; 254: 472–8
   PubMed Web of Science ®Google Scholar
• Potena L, Frascaroli G, Grigioni F, Lazzarotto T, Magnani G, Tomasi L, et al. Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation. 2004; 109: 532–6
   PubMed Web of Science ®Google Scholar